Taking Complexity to the Next Level

During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).

Approaching drug development with highly potent compounds gives rise to specific challenges, which can ultimately lead to increased costs and complex processes. In his presentation, Janssen will highlight ways in which companies can facilitate rapid time to clinic and market and will use a case study to emphasize the advantages of seamless integration of highly potent API and ADC operations.

HPAPIs and ADCs – a journey through high potencyTuesday Nov. 5, 201913:50–14:20ICSE Theatre (120G43)